GlobeNewswire by notified

Ergomed strongly positioned for future growth in new partnership with Permira



Ergomed strongly positioned for future growth
in new partnership with Permira

  • Permira completes acquisition of Ergomed for £703.1 million
  • Through this partnership, Permira will support Dr. Miroslav Reljanović and the team in Ergomed’s next phase by accelerating the growth of the business
  • Investment to focus on commercial expansion, technology and strategic M&A

Guildford, UK and London, UK – 14 November 2023: Ergomed plc ("Ergomed") and Permira Advisers LLP ("Permira"), are pleased to announce the completion of the acquisition of Ergomed by funds advised by Permira (the “Permira Funds”) for £703.1 million.

Ergomed is a differentiated Pharmacovigilance (“PV”) and Contract Research Organisation (“CRO”) platform with a strong track record in the complex oncology and rare diseases spaces and a reputation for high-quality, bespoke, customer centric delivery across its services.

Ergomed operates in growing markets which benefit from increasing complexity, regulatory requirements and outsourcing rates. Dr. Miroslav Reljanović, founder and Executive Chairman, and the management team have made strong progress in recent years, strengthening both CRO and PV capabilities organically and through acquisitions.

Permira has an extensive track record in the pharma and pharma services sector, deploying capital and expertise into growth-orientated businesses and partnering with founders and management teams in achieving their strategic ambitions. Permira’s deep industry-specific knowledge and strong network in the healthcare space will allow it to support the next phase of growth for Ergomed by investing in the business’ commercial expansion, technology transformation and geographic reach, as well as providing additional capital to undertake strategic acquisitions.

Dr. Miroslav Reljanović, Executive Chairman of Ergomed, said: “With a strong commitment to service quality and customer service, Ergomed has grown significantly to become a global, geographically diversified player in the CRO and PV sectors. Permira is a highly experienced healthcare investor with a track record of building successful global businesses, which will support us to build on the foundations we have created. Permira brings operational expertise, a global network, capital and, equally importantly, a like-minded approach to how to accelerate our growth. We believe the acquisition will significantly increase our ability to invest in our geographical expansion, commercial infrastructure, and technology, and to execute strategic M&A in both the CRO and PV businesses.”

Silvia Oteri, Partner and Global Head of Healthcare at Permira, said: “We are delighted to complete the acquisition of Ergomed, a medic-led, high quality and fast-growing pharma services platform. It is a privilege to be partnering with Miro and his team, who had the vision of creating a leading outsourcing partner in pharmacovigilance and in oncology and rare disease clinical development, helping clients safely develop and commercialise complex and often life-saving therapies for patients. Through this partnership, we will help Miro and the team to further build and accelerate on the very strong foundation they have already laid.”


Ergomed+44 (0) 1483 307 920
Dr. Miroslav Reljanović (Executive Chairman)                                         
Jonathan Curtain (Chief Financial Officer)
Keith Byrne (Senior Vice President, Capital Markets and Strategy)

ICR Consilium (PR adviser to Ergomed)                              +44 (0) 20 3709 5700
Chris Gardner
Matthew Neal

Headland Consultancy Limited (PR adviser to Permira)                                       +44 (0) 20 3805 4822
Lucy Legh
Rob Walker
Charlie Twigg

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit:

About Permira

Permira is a global investment firm that backs successful businesses with growth ambitions. Founded in 1985, the firm advises funds with total committed capital of approximately €77bn and makes long-term majority and minority investments across two core asset classes, private equity and credit. The Permira private equity funds have made approximately 300 private equity investments in four key sectors: Technology, Consumer, Healthcare and Services.

The Permira funds have an extensive track record in healthcare investing, having deployed over €4 billion in approximately 20 companies to scale some of the most innovative healthcare businesses globally across specialty pharma, medical devices, strategic outsourcing platforms and healthcare technology. Current and previous investments from the Permira funds in the sector include Kedrion, Cambrex, Neuraxpharm, LSNE, Quotient Sciences, I-MED and Althea.

Permira employs over 500 people in 15 offices across the United States, Europe and Asia. For more information visit

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC1.12.2023 19:00:00 CET | Press release

Regulated Information Leuven, BELGIUM, Boston, MA, US – December 1, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a first transparency notification on November 22, 2023, from Atlas Special Opportunities, LLC indicating that as of November 13, 2023, it held 0 shares of the then outstanding 3,112,043,514 shares, and therefore crossed below the threshold (3%) by virtue of the sale of voting securities. See Annex 1. Oxurion received a second transparency notification on November 29, 2023, from Atlas Special Opportunities, LLC indicating that as of November 17, 2023, it held 241,545,893 shares of the then outstanding 3,489,458,972 shares, and therefore crossed above the threshold (5%) by virtu

Havila Kystruten AS: Regnskap for tredje kvartal 20231.12.2023 18:34:33 CET | Pressemelding

September var første måned med full drift av alle fire skip. Til tross for forsinkelse av Havila Polaris og Havila Pollux i Q3, ble gjennomsnittlig belegg 70 % og gjennomsnittlig lugarrate kr 4 466. Inntektene er naturligvis preget av forsinkelsene og lavere enn forventet, men selskapet ser en positiv inntektsutvikling fra 2. kvartal og videre ut året. I forbindelse med refinansiering er driftskostnadene påvirket av ekstraordinære kostnader knyttet til juridiske og finansielle rådgivere. Regnskap og balanse påvirkes av valutasvingningene, og selskapet sikrer sine valutaforpliktelser med salg i valuta. Selskapet legger til grunn en normalisert drift av fire skip fremover, uten ekstraordinære kostnader. Selskapet har ambisjoner om et gjennomsnittlig belegg på 80 % for 2024, hvorav 45 % av all kapasitet allerede er solgt. Interessen for Havila Kystruten øker stadig i både inn- og utland, og positive tilbakemeldinger om produkt og konsept mottas på daglig basis. Resultat for 3. kvartal 202

Havila Kystruten : Third quarter 2023 accounts1.12.2023 18:34:33 CET | Press release

September marked the first month of full operation for all four ships. Despite the delays with Havila Polaris and Havila Pollux in Q3, the average occupancy rate reached 70%, with an average cabin rate of NOK 4,466. Revenues are naturally affected by the delays and lower than expected, but the company sees a positive revenue trend from the 2nd quarter and onward throughout the year. In connection with refinancing, operating costs were affected by extraordinary expenses related to legal and financial advisors. Currency fluctuations have had an impact on the financial statements and balance sheet, and the company is hedging its currency commitments through currency sales. The company assumes normalized operation of four ships going forward, without extraordinary costs. The company aims for an average occupancy rate of 80% for 2024, with 45% of all capacity already sold. Interest in Havila Kystruten is continually growing both domestically and internationally, with positive feedback on th

Resultat af aktietilbagekøb1.12.2023 17:41:01 CET | pressemeddelelse

Selskabet meddelte i selskabsmeddelelse 30/2023, at man havde besluttet at iværksætte et aktietilbagekøb på køb af optil 1.000.000 aktier til kurs 2.50 svarende til maksimalt DKK 2.5 mio. i perioden 22. november – 1. december 2023, begge dage inklusive. I hele perioden har der været indlagt en synlig stående budordrer i kurs 2.50, så markedet løbende har kunne følge tilbagekøbets udvikling, og som det også fremgik af selskabsmeddelelse 30/2023, så stod alle insidere tilbage for selskabets aktionærer, så insidere som ønskede at sælge aktier kun kunne tilbagesælge aktier den sidste dag, dvs. fra og med fredag d. 1. december 2023 kl. 09.00. Resultatet af insidernes evt. frasalg vil fremgå af en separat meddelelse. Resultatet af aktietilbagekøbsprogrammet blev at selskabet har tilbagekøbt 19.687 aktier til kurs 2.50 svarende til DKK 49.217,50. Selskabet ejer pr. dags dato totalt 4.854.063 egne aktier svarende til 9,06 % af selskabets aktiekapital. Det samlede antal aktier i virksomheden er

Registration of share capital increase in IDEX Biometrics 1 Dec 20231.12.2023 17:30:00 CET | Press release

Reference is made to the notice on 21 November 2023 regarding employees having exercised 389,608 incentive subscription rights at NOK 0.15 per share. The capital increase has been registered and the shares will be delivered soonest. Following the issue, the company's share capital is NOK 209,551,597.20 divided into 1,397,010,648 shares, each with a nominal value of NOK 0.15. For further information contact: Marianne Bøe, Investor Relations E-mail: Tel: +47 918 00186 About IDEX Biometrics IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As